SCHEMBL31220195

SCHEMBL31220195

COc1ccc(Cn2ccc(C(N)=O)n2)cc1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CACNA1G O43497 3/20 0.53
CACNA1H O95180 3/20 0.53
CACNA1I Q9P0X4 3/20 0.53
ALDH1A1 P00352 2/20 0.47
HDAC1 Q13547 2/20 0.45
KDM1A O60341 1/20 0.45
HDAC2 Q92769 1/20 0.45
HDAC8 Q9BY41 1/20 0.45
HDAC6 Q9UBN7 1/20 0.45
HDAC5 Q9UQL6 1/20 0.45
KMT2A Q03164 3/20 0.44
NPC1 O15118 3/20 0.44
RAB9A P51151 3/20 0.44
MEN1 O00255 2/20 0.44
CYP19A1 P11511 1/20 0.44
CMA1 P23946 1/20 0.44
PDE8B O95263 1/20 0.44
CA1 P00915 1/20 0.44
CA2 P00918 1/20 0.44
PARP1 P09874 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3704214 0.87 CACNA1G (0.57) CACNA1GCACNA1HCACNA1IALDH1A1HDAC1
SCHEMBL1906943 0.86 KMT2A (0.60) CACNA1GCACNA1HCACNA1IALDH1A1HDAC1
SCHEMBL4726770 0.84 SMN1; SMN2 (0.50) CACNA1GCACNA1HCACNA1IALDH1A1HDAC1
SCHEMBL29705220 0.83 CACNA1G (0.54) CACNA1GCACNA1HCACNA1IALDH1A1HDAC1
SCHEMBL8865422 0.82 CACNA1G (0.49) CACNA1GCACNA1HCACNA1IALDH1A1HDAC1
SCHEMBL1047744 0.81 CACNA1G (0.55) CACNA1GCACNA1HCACNA1IALDH1A1HDAC1
SCHEMBL4288842 0.80 HDAC1 (0.56) CACNA1GCACNA1HCACNA1IALDH1A1HDAC1
SCHEMBL16554654 0.80 SCD (0.57) ALDH1A1HDAC1KMT2ANPC1RAB9A
SCHEMBL4676077 0.79 CACNA1G (0.50) CACNA1GCACNA1HCACNA1IALDH1A1HDAC1
SCHEMBL166508 0.77 ALDH1A1 (0.53) CACNA1GCACNA1HCACNA1IALDH1A1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260078127-A1 HETEROBICYCLIC AMIDES AS INHIBITORS OF CD38 BOEHRINGER INGELHEIM INT (DE) 2026-03-19 US disclosed
US-20240368167-A1 HETEROBICYCLIC AMIDES AS INHIBITORS OF CD38 BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2024-11-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240368167-A1 HETEROBICYCLIC AMIDES AS INHIBITORS OF CD38 CD38, PARP12, ENTPD2 CACNA1G 3166/4885CACNA1H 3394/4885CACNA1I 2195/4885
US-20260078127-A1 HETEROBICYCLIC AMIDES AS INHIBITORS OF CD38 CD38, CD22, CD79B CACNA1G 1189/4885CACNA1H 1127/4885CACNA1I 1479/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.